The in-vivo antifungal activity of benanomicin A administered intravenously or subcutaneously was compared with that of amphotericin B and fluconazole using animal models of systemic infections with Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans. The efficacy of benanomicin A in C. albicans infection was more pronounced when administered in multiple doses than in a single dose. This was also true of fluconazole, but not of amphotericin B, which showed no difference between single and multiple dosings. 
Introduction
Benanomicin A is an antifungal antibiotic produced by Actinomadura spadix MH193-16F4, 1 and shows a broad antimicrobial spectrum against a wide range of fungi including pathogens of endemic and opportunistic mycoses. 2 The promising results of the in-vitro study of benanomicin A tempted us to examine the in-vivo activity of the antibiotic.
The present paper describes the efficacy of benanomicin A compared with that of amphotericin B and fluconazole in mice systemically infected with Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans.
Materials and methods

Antifungal drugs
Benanomicin A sodium salt was prepared at the Pharmaceutical Research Center of Meiji Seika Kaisha, Ltd, Yokohama. It was dissolved in sterile saline, and passed through a Millipore filter (0.45 m). The filtered solution was subjected to serial two-fold dilutions with sterile saline unless otherwise stated. Each of the solutions was divided into five parts corresponding to five administrations, and kept in a refrigerator before use. plex; Bristol-Myers Squibb, Tokyo, Japan) with 50 mL of 5% dextrose in water followed by two-fold series of dilutions with 5% dextrose, unless otherwise stated. Fluconazole (0.2% solution) was the product of Pfizer Pharmaceutical Co., Tokyo, Japan (Diflucan) and was diluted in two-fold series with sterile saline for use. For the treatment of murine cryptococcosis, benanomicin A was dissolved in sterile saline at a concentration of 24 mg/mL, and diluted in two-fold series with sterile saline. Amphotericin B was dissolved in 5% dextrose at a concentration of 3 mg/ mL, and diluted in two-fold series with 5% dextrose. For the life-prolonging and mycological studies with murine candidosis, the drug solution of 5 mg/mL (benanomicin A and fluconazole) or 0.5 mg/mL (amphotericin B) was diluted in ten-fold series with saline or 5% dextrose, respectively.
Fungal pathogens
C. albicans TIMM1768, A. fumigatus TIMM1775 and C. neoformans TIMM1855 were used for challenge. They were stock cultures of the Research Center for Medical Mycology, Teikyo University, originally isolated from hospitals in Japan, and were stored at 80°C in 10% glycerol until use. For each study, fresh cultures were maintained on Sabouraud dextrose agar (SDA) or potato dextrose agar (Nissui Seiyaku Co., Tokyo, Japan). The susceptibility of the three organisms to benanomicin A and the other reference drugs measured by agar dilution technique is given in Table I .
Animals
Male Crj:CD1 albino mice (ICR mice; Charles River Breeding Laboratories, Atsugi, Japan), 4 weeks old, were used for producing experimental systemic infections with C. albicans and A. fumigatus, and female Crj:CD-1 (ICR) mice, 5 weeks old, for C. neoformans infection. Mice were housed in air-conditioned rooms at 22-24°C on a 12-h light/12-h dark cycle, and were allowed free access to food and water ad libitum unless otherwise stated. Mice were randomized into treatment and control groups of five and two animals respectively. Animals subjected to viable cells observation (five mice per group), and histological examination (two mice per group) were predetermined at the start of experiments of murine candidosis. Viable C. albicans cells in the kidneys of the infected mice were counted 5 and 14 days after the challenge. Five mice in each group were killed by ip injection with 2 mg of pentobarbital sodium on the scheduled day. Both kidneys of each animal were excised, weighed and homogenized in 5 mL of saline with a Teflon homogenizer (Nissan Riko, Tokyo, Japan) under sterile conditions. Aliquots of the tissue homogenate and ten-fold dilutions were plated and cultured on candida GE agar (Nissui) plates in duplicate. Fungal colonies on the plate were counted after incubation at 27°C for 2 days.
Studies with murine candidosis
For histopathological examination, infected mice, two per group, having received iv treatment with benanomicin A at a daily dosage of 5 mg/kg for 5 consecutive days were killed by anaesthesia 5 days and 14 days after the challenge and both kidneys excised from each animal. Each kidney was cut into six pieces with a razor blade, and fixed with 10% formalin buffered with 1/7.5 M sodium phosphate (pH 7.0). Thin paraffin sections approximately 4 m thick were stained with periodic acid-Schiff (PAS) and haematoxylin and subjected to histopathological examinations. Kidneys were also removed from infected non-treated mice in the same way.
Studies with murine aspergillosis
A. fumigatus TIMM1775 was grown on potato-dextrose agar at 27°C for 3 weeks. Conidia were harvested and suspended in sterile saline containing 0.05% Tween 80. The suspension was crushed with a pestle in a sterile mortar, and filtered through a glass pad of 180 mesh. The number of conidia in the filtrate was counted using a haemocytometer on a microscope, and viable cells were counted independently by using potato-dextrose agar. The conidia suspension was finally adjusted to 6 10 6 cfu of conidia per mL. Mice were injected intravenously with 0.2 mL of the suspension. Each of the drug solutions (0.2 mL) was administered iv or sc into mice 1 h, or 1, 2, 3 or 4 days after infection. The dosage range for the determination of ED 50 values was 300-2.35 mg/kg for benanomicin A, 10-0.0195 mg/kg for amphotericin B and 50-6.25 mg/kg for fluconazole. Sterile saline was injected as vehicle into control mice. All the infected control mice died within 7 days after the challenge. On day 14 all surviving animals were killed and their lungs were removed, minced and plated on SDA plates. All plates were incubated at 37°C for 2 days, and the number of colonies grown on each plate was recorded.
Studies with murine cryptococcosis
C. neoformans TIMM1855 was grown on SDA plates at 27°C for 2 days. Organisms harvested were resuspended in sterile saline and adjusted to 1 10 7 cfu/mL, after viable cell counting. The yeast suspension thus prepared was inoculated in a volume of 0.1 mL into the tail vein of mice. Each of the drug solutions (0.1 mL) was administered sc starting 1 h after the challenge and injections continued once a day for 5 days. The dosage range for the determination of ED 50 values was 120-7.5 mg/kg for benanomicin A and 15-1.8 mg/kg for amphotericin B. Phosphate buffer (1/7.5 M, pH 7.0) was injected as vehicle. All the infected control animals died within 9 days after challenge. Mice were observed daily for mortality until the end of the 3-week experimental period. All survivors were killed 21 days after the challenge under anaesthesia for culture study. The brain, excised from mice aseptically, was minced and serial dilutions of the homogenate were implanted on SDA plates to measure viable counts as described above.
Statistical data processing
The ED 50 values with 95% confidence limits were calculated from the survival rate recorded on day 14 (for C. albicans and A. fumigatus infections) or on day 21 (for C. neoformans infection) using the Probit method. Table II shows the results of experiments in which C. albicans-infected mice received benanomicin A, amphotericin B or fluconazole iv in once-daily doses given for 1, 3 or 5 days. With increasing numbers of doses, the ED 50 value (mg/kg/day) for benanomicin A decreased remarkably, the value for a single dose (37.8 mg/kg/day) being approximately 40 times as high as that for five doses (0.96 mg/kg/day). A similar multiple dosing effect, although not as remarkable as that for benanomicin A, was also seen with fluconazole. This was not true of amphotericin B, whose ED 50 value was virtually the same irrespective of the number of doses.
Results
Efficacy in C. albicans-infected mice
The in-vivo activity of benanomicin A was confirmed by culture studies performed using kidneys of the treated and untreated mice with C. albicans infection. As summarized in Table III , benanomicin A showed a dose-dependent eradication of the pathogen from the kidneys at day 14. Three of five mice treated with benanomicin A at a daily dosage of 50 mg/kg showed complete eradication of the candida cell from kidneys and all of the animals survived for 21 days of the experimental period. Partial eradication was observed at a dose of 5 mg/kg with 20% mortality, but lower dosages (0.5 and 0.05 mg/kg) showed no eradication and no survival.
Amphotericin B caused dose-dependent eradication of the pathogen from the kidney, except for the 5 mg dosage group, in which all mice died from drug toxicity. The 0.5 mg dose group showed complete eradication of the pathogen, but lower dose (0.05 and 0.005 mg/kg) groups showed essentially no eradication with 60% mortality. An increase of the life-span and partial eradication of the pathogen were observed also in mice treated with fluconazole at doses of 0.5, 5 and 50 mg/kg, but the mycological curative effect of fluconazole was much lower than that of benanomicin A or amphotericin B.
To confirm the therapeutic efficacy of benanomicin A, specimens taken from renal tissues in the experiment described in Table III were examined histopathologically (see Figure) . The untreated control showed an exuberant pseudohyphal growth of C. albicans in the centre of medullary abscesses ( Figure, panels a and b) . In contrast, the benanomicin A (5 mg/kg)-treated group examined 5 days after challenge showed a small number of minute abscesses with only few mainly yeast-like cells of candida ( Figure, panels c and d) . Furthermore, PAS stainability of fungal cells found in renal abscesses of benanomicin A-treated mice was markedly decreased compared with fungal cells in untreated mice ( Figure, panels b and d) . The therapeutic effects were observed also with the specimen taken 14 days after the challenge, but the effect was less noticeable because regrowth of the pathogen o c c u r r e d . Table IV shows the therapeutic efficacy in terms of ED 5 0 values of benanomicin A and the two reference drugs administered by the sc and iv routes once daily for five consecutive days in mice systemically infected with C. albicans. The efficacy of benanomicin A was lower than that of amphotericin B but higher than that of fluconazole. Comparison of the ED 5 0 value of sc benanomicin A with that of the iv administration showed that the value of the former was slightly lower. This was also the case in single administration (sc dose, 0.52 mg/kg; iv dose, 0.90 mg/kg) and with three administrations (sc dose, 0.069 mg/kg; iv dose, 0.085 m g / k g ) .
Efficacy in A. fumigatus-infected mice
Table IV also shows ED 50 values of benanomicin A and the other two drugs administered sc and iv once daily for five consecutive days starting 1 h after infection to mice infected via the iv route with a lethal dose of A. fumigatus. The ED 50 value of sc benanomicin A (19.0 mg/kg day) was one-third that of the iv one (56 mg/kg/day). In contrast, the ED 50 value of sc doses of a Drugs were given intravenously once daily for five consecutive days starting 1 h after infection. b Number in parentheses indicates survivors with culture-negative kidney at 14 days. c Culture studies were performed 2 weeks after the start of this experiment.
amphotericin B was similar to that of iv doses of the antibiotic (0.067 versus 0.04 mg/kg/day). Sc or iv administered fluconazole showed no efficacy in doses up to 50 mg/kg/day under these experimental conditions.
Efficacy in C. neoformans-infected mice
The therapeutic efficacy of sc doses of benanomicin A and amphotericin B against murine cryptococcosis was examined using mice infected iv with a lethal dose (1.56 10 6 cfu/mouse) of C. neoformans. As shown in Table V , both antibiotics administered sc once daily for five consecutive days starting 1 h after challenge, increased the survival rate and/or prolonged the survival time dose-dependently, with ED 50 values of 21.5 and 5.6 mg/kg/day, respectively. Table V also shows the number of C. neoformans cells recovered from the brain of mice treated with these drugs. Both benanomicin and amphotericin B were effective in prolonging the survival of mice, but eradication of fungal cells from the brain was poor under the conditions examined.
Discussion
The present study showed that either iv or sc administered benanomicin A is effective in systemic murine infection with C. albicans, A. fumigatus and C. neoformans, major opportunistic pathogens of deep mycoses in humans. The in-vivo efficacy of benanomicin A in these murine models of systemic mycoses was evidenced by an increase in lifespan, clearance of pathogens from the The ED 50 values of benanomicin A in these murine models of systemic opportunistic fungus infections were intermediate between those of amphotericin B and fluconazole. It appears from these data that the in-vivo activity of benanomicin A and amphotericin B in animal models of fungal infection is correlated with the MIC value of a respective drug, while fluconazole has more potent activity in vivo than that expected from its activity in vitro. 3 The activity of benanomicin A in vivo can be characterized as follows. Firstly, it is effective against all three major opportunistic fungal infections, namely, candidiasis, aspergillosis and cryptococcosis. Secondly, the in-vivo activity of multiple dosing is greater than that of a single dose. When benanomicin A was administered in a single dose to mice by the iv and sc routes, the half-life values were about 1.8 h and 2.6 h, respectively (data not shown). Fluconazole showed a half-life of 4.5 h in mice by iv administration, 4 and amphotericin B showed a half-life of 10 h in rats. 5 The shorter half-life of benanomicin A may be the reason for its increasing efficacy with multiple administration.
The third characteristic is that, like amphotericin B but unlike fluconazole, benanomicin A reduces the number of pathogens in the target organs in a dose-dependent manner. Both benanomicin A and amphotericin B show fungicidal action against C. albicans,2 and this may be reflected in clearance of the pathogens from the target organ. The fourth feature of benanomicin A is its wide range of effective doses in vivo. For example, the anti- a Each mouse was infected intravenously with C. neoformans at a dose of 1 10 6 cfu. b Drug was given subcutaneously once a day for 5 days starting 1 h after the challenge. c Deaths within 3 weeks after fungal inoculation. biotic protected mice from lethal C. albicans infection over the dose range 18.75 mg/kg to 300 mg/kg. The low acute toxicity of benanomicin A to animals allows the use of such high doses. 6 Life-threatening deep mycoses have recently increased, especially in immunocompromised hosts such as patients undergoing cancer chemotherapy or with acquired immunodeficiency syndrome, and new antifungal agents with better clinical usefulness are eagerly required. The potent efficacy of benanomicin A in murine models of deep mycoses suggests that it may be of value for treating humans with such infections.
